Atrial fibrillation. The most common arrhythmia

Texas Heart Institute Journal

Volumn 27, Issue 3, 2000, Pages 257-267

  Wyndham, Christopher R C ^a  

^a North Texas Heart Center   (United States)

Author keywords

Anti arrhythmia agents therapeutic use; Anticoagulants therapeutic use; Atria flutter therapy; Atrial fibrillation physiopathology; Atrial fibrillation therapy; Cardiac pacing, artiticial; Catheter ablation; Thromboembolism prevention and control

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL AFFECTING AGENT; CLOPIDOGREL; DIGITALIS; DILTIAZEM; DISOPYRAMIDE; FLECAINIDE; PROPAFENONE; SOTALOL; VERAPAMIL; WARFARIN;

ANTICOAGULATION; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED DISEASE; ECHOGRAPHY; HEART ATRIUM FIBRILLATION; HEART SURGERY; HUMAN; PACEMAKER; PATHOGENESIS; REVIEW; RISK FACTOR; SINUS RHYTHM; SURGICAL TECHNIQUE; THROMBOEMBOLISM; VASCULAR SURGERY; WOLFF PARKINSON WHITE SYNDROME;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; HUMANS; PACEMAKER, ARTIFICIAL;

EID: 0033774879     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: Roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation
2. Atrial electrophysiologic remodeling: Another vicious circle?
3. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation
4. + current in a chronic dog model of atrial fibrillation
5. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat
6. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation
7. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation
8. Treatment with a T-type calcium channel blocker prevents atrial fibrillation caused by tachycardia induced atrial remodeling
9. Immediate and long-term prevention of thromboembolism in atrial fibrillation
10. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators
11. Cardioversion guided by transesophageal echocardiography: The ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion Using Transesophageal Echocardiography
12. Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (The ACUTE Multicenter Study). Steering and Publications Committees of the ACUTE Study
13. Transesophageal echocardiography facilitated cardioversion from atrial fibrillation: Short term safety and implications regarding maintenance of sinus rhythm
14. Atrial fibrillation follow-up investigation of rhythm management - The AFFIRM study design. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators
15. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators
16. Conversion of recent-onset atrial fibrillation to sinus rhythm: Effects of different drug protocols
17. Antiarrhythmic drug therapy in the management of atrial fibrillation
18. Atrial fibrillation: Maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: The PIAF trial
19. The long-term pharmacologic management of atrial fibrillation for control of rate and rhythm
20. Long-term follow-up after radiofrequency ablation of paroxysmal supraventricular tachycardia in patients with tachycardia-induced atrial fibrillation
21. Pathogenesis of atrial flutter
22. Long-term outcome of radiofrequency catheter ablation for typical atrial flutter: Risk prediction of recurrent arrhythmias
23. High-density mapping of activation through an incomplete isthmus ablation line
24. Radiofrequency catheter ablation of common atrial flutter: Significance of palpitations and quality-of-life evaluation in patients with proven isthmus block
25. Atrial fibrillation after radiofrequency ablation of type I atrial flutter: Time to onset, determinants, and clinical course
26. Hybrid pharmacologic and ablative therapy - A novel and effective approach for the management of atrial fibrillation
27. Uncommon atrial flutter: Characteristics, mechanisms, and results of ablative therapy
28. An 8 1/2 year clinical experience with surgery for atrial fibrillation
29. Mid term results of surgery for atrial fibrillation in mitral patients: Comparison of three surgical procedures [abstract]
30. Left atrial reduction for chronic atrial fibrillation associated with mitral valve disease
31. A catheter-based curative approach to atrial fibrillation in humans
32. Successful catheter ablation of atrial fibrillation
33. Atrial mapping and radiofrequency catheter ablation in patients with idiopathic atrial fibrillation. Electrophysiological findings and ablation results
34. Long-term follow-up after right atrial radiofrequency catheter treatment of paroxysmal atrial fibrillation
35. Right atrial compartmentalization using radiofrequency catheter ablation for management of patients with refractory atrial fibrillation
36. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation
37. Anatomy of the left atrium: Implications for radiofrequency ablation of atrial fibrillation
38. A focal source of atrial fibrillation treated by discrete radiofrequency ablation
39. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: Electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation
40. Catheter ablation of the atrioventricular junction with radiofrequency energy
41. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation
42. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome. Relevance of clinical characteristics and pacing modalities
43. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats
44. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome
45. Electrical remodeling of the atria following loss of atrioventricular synchrony: A long-term study in humans
46. Interatrial septum pacing: A new approach to prevent recurrent atrial fibrillation
47. Bachmann's Bundle Pacing Trial Centers. Bachmann's bundle pacing for the prevention of atrial fibrillation. Initial trends in a multicenter randomized prospective study
48. Effects of different atrial pacing modes on atrial electrophysiology: Implicating the mechanism of biatrial pacing in prevention of atrial fibrillation
49. Multicenter experience with single and dual site right atrial pacing in refractory atrial fibrillation
50. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention
51. Time dependence and pattern of atrial fibrillation recurrences after single and dual site right atrial pacing
52. Dual site right atrial pacing in paroxysmal atrial fibrillation without bradycardia (NIPP-AF Study)
53. Biatrial synchronous pacing for atrial arrhythmia prevention: The SYNBIAPACE Study
54. Design and implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) clinical trial. DAPPAF Phase I Investigators
55. Effect of underlying cardiac disease on the ambulatory use of the Metrix automatic implantable atrial defibrillator
56. Clinical experience with a dual chamber implantable cardioverter defibrillator in patients with atrial fibrillation and flutter
57. Effect of the implantable atrial defibrillator on the natural history of atrial fibrillation